(Q48020552)

7 February 2018

title

Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition (English)

1 reference

7 February 2018

author

Xiaohai Wang

4

1 reference

7 February 2018

Christopher Winrow

20

1 reference

7 February 2018

author name string

Jason M Uslaner

1

1 reference

7 February 2018

Spencer J Tye

2

1 reference

7 February 2018

Donnie M Eddins

3

1 reference

7 February 2018

Steven V Fox

5

1 reference

7 February 2018

Alan T Savitz

6

1 reference

7 February 2018

Jacquelyn Binns

7

1 reference

7 February 2018

Christopher E Cannon

8

1 reference

7 February 2018

Susan L Garson

9

1 reference

7 February 2018

Lihang Yao

10

1 reference

7 February 2018

Robert Hodgson

11

1 reference

7 February 2018

Joanne Stevens

12

1 reference

7 February 2018

Mark R Bowlby

13

1 reference

7 February 2018

Pamela L Tannenbaum

14

1 reference

7 February 2018

Joseph Brunner

15

1 reference

7 February 2018

Terrence P Mcdonald

16

1 reference

7 February 2018

Anthony L Gotter

17

1 reference

7 February 2018

Scott D Kuduk

18

1 reference

7 February 2018

Paul J Coleman

19

1 reference

7 February 2018

John J Renger

21

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 April 2013

1 reference

7 February 2018

Science Translational Medicine

published in

1 reference

7 February 2018

volume

5

1 reference

7 February 2018

issue

179

1 reference

7 February 2018

page(s)

179ra44

1 reference

7 February 2018

Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders.

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Prevalence and consequences of sleep disorders in a shift worker population

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Prevalence, burden, and treatment of insomnia in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The safety and tolerability of zolpidem--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Association of road-traffic accidents with benzodiazepine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Residual effects of sleep medication on driving ability

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Zolpidem and traffic safety - the importance of treatment compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Sleep neurobiology from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Orexin receptors: pharmacology and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Effects of daytime administration of zolpidem versus triazolam on memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Comparison of the daytime sleep and performance effects of zolpidem versus triazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Sedative, memory, and performance effects of hypnotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The alpha1 subunit of the GABA(A) receptor modulates fear learning and plasticity in the lateral amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Drug interactions at GABA(A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

GABA-based therapeutic approaches: GABAA receptor subtype functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Which GABAA-receptor subtypes really occur in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Differential expression of orexin receptors 1 and 2 in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Stimulation of cortical acetylcholine release by orexin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The action of orexin A on passive avoidance learning. Involvement of transmitters

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

Sub-chronic administration of zolpidem affects modifications to rat sleep architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005213

10.1126/SCITRANSLMED.3005213

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018